Ambalal Sarabhai Enterprises Ltd
Incorporated in 1977, Ambalal Sarabhai Enterprises Ltd is in the business of manufacturing Pharmaceuticals and Electronics[1]
- Market Cap ₹ 368 Cr.
- Current Price ₹ 48.0
- High / Low ₹ 70.0 / 20.9
- Stock P/E
- Book Value ₹ 4.75
- Dividend Yield 0.00 %
- ROCE 11.5 %
- ROE 13.4 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Debtor days have improved from 225 to 29.5 days.
Cons
- Stock is trading at 10.0 times its book value
- Company has low interest coverage ratio.
- Promoter holding is low: 30.8%
- Company has a low return on equity of 5.37% over last 3 years.
- Working capital days have increased from -1,682 days to 286 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
21.27 | 16.67 | 15.67 | 15.25 | 6.98 | 1.51 | 0.92 | 0.00 | 0.00 | 0.00 | 0.13 | 3.71 | 3.20 | |
35.37 | 33.49 | 29.02 | 27.30 | 28.62 | 14.47 | 21.76 | 8.86 | 7.86 | 11.69 | 5.71 | 8.87 | 10.59 | |
Operating Profit | -14.10 | -16.82 | -13.35 | -12.05 | -21.64 | -12.96 | -20.84 | -8.86 | -7.86 | -11.69 | -5.58 | -5.16 | -7.39 |
OPM % | -66.29% | -100.90% | -85.19% | -79.02% | -310.03% | -858.28% | -2,265.22% | -4,292.31% | -139.08% | -230.94% | |||
17.29 | 18.83 | 3.43 | 14.17 | 95.94 | -0.63 | 24.49 | 6.46 | 24.61 | 3.16 | 9.47 | 9.75 | 7.07 | |
Interest | 8.44 | 6.75 | 9.12 | 7.91 | 1.99 | 2.62 | 1.05 | 0.62 | 0.46 | 0.56 | 0.25 | 0.11 | 0.18 |
Depreciation | 1.40 | 12.48 | 1.52 | 3.36 | 14.62 | 2.45 | 0.42 | 0.40 | 0.39 | 0.38 | 0.19 | 0.15 | 0.12 |
Profit before tax | -6.65 | -17.22 | -20.56 | -9.15 | 57.69 | -18.66 | 2.18 | -3.42 | 15.90 | -9.47 | 3.45 | 4.33 | -0.62 |
Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 20.80% | -10.18% | 166.06% | -13.45% | 2.20% | 0.84% | 14.49% | 5.31% | |
-6.65 | -17.22 | -20.57 | -9.15 | 45.68 | -20.57 | -1.44 | -3.88 | 15.55 | -9.39 | 2.96 | 4.11 | -0.99 | |
EPS in Rs | -0.87 | -2.25 | -2.68 | -1.19 | 5.96 | -2.68 | -0.19 | -0.51 | 2.03 | -1.23 | 0.39 | 0.54 | -0.12 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | -14% |
5 Years: | 32% |
3 Years: | % |
TTM: | -8% |
Compounded Profit Growth | |
---|---|
10 Years: | 9% |
5 Years: | 19% |
3 Years: | -32% |
TTM: | -105% |
Stock Price CAGR | |
---|---|
10 Years: | 32% |
5 Years: | 27% |
3 Years: | 24% |
1 Year: | 121% |
Return on Equity | |
---|---|
10 Years: | -29% |
5 Years: | 10% |
3 Years: | 5% |
Last Year: | 13% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 |
Reserves | -26.16 | -43.57 | -64.34 | -73.49 | -27.80 | -46.41 | -47.98 | -51.85 | -36.39 | -45.85 | -42.93 | -38.79 | -40.23 |
16.89 | 22.15 | 27.27 | 30.10 | 29.54 | 22.13 | 11.07 | 11.07 | 11.00 | 11.14 | 9.77 | 8.23 | 7.76 | |
91.56 | 87.50 | 97.45 | 103.24 | 65.13 | 63.81 | 91.28 | 102.78 | 73.35 | 58.14 | 39.53 | 33.67 | 32.37 | |
Total Liabilities | 158.92 | 142.71 | 137.01 | 136.48 | 143.50 | 116.16 | 131.00 | 138.63 | 124.59 | 100.06 | 83.00 | 79.74 | 76.53 |
60.03 | 48.08 | 46.41 | 42.66 | 20.60 | 16.43 | 14.98 | 14.65 | 14.48 | 13.97 | 13.00 | 12.86 | 12.85 | |
CWIP | 0.10 | 0.10 | 0.10 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 58.49 | 57.99 | 56.16 | 56.29 | 82.91 | 76.19 | 55.88 | 55.97 | 56.43 | 26.58 | 25.54 | 25.54 | 25.54 |
40.30 | 36.54 | 34.34 | 37.43 | 39.99 | 23.54 | 60.14 | 68.01 | 53.68 | 59.51 | 44.46 | 41.34 | 38.14 | |
Total Assets | 158.92 | 142.71 | 137.01 | 136.48 | 143.50 | 116.16 | 131.00 | 138.63 | 124.59 | 100.06 | 83.00 | 79.74 | 76.53 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-8.73 | -1.01 | 1.43 | -12.05 | -69.37 | -3.67 | -12.66 | -3.27 | -4.53 | -10.42 | -7.79 | 1.70 | |
13.01 | 1.29 | 2.34 | 12.70 | 75.22 | 8.64 | 26.14 | 2.37 | 4.92 | 15.76 | 20.77 | 0.43 | |
-4.77 | 0.00 | -4.00 | -0.75 | -2.56 | -8.14 | -12.15 | -0.44 | -0.42 | -0.32 | -16.46 | -3.76 | |
Net Cash Flow | -0.49 | 0.28 | -0.23 | -0.10 | 3.30 | -3.17 | 1.33 | -1.33 | -0.03 | 5.02 | -3.47 | -1.63 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 61.78 | 83.64 | 78.26 | 37.34 | 1.57 | 0.00 | 0.00 | 421.15 | 29.51 | |||
Inventory Days | 34.14 | 53.77 | 5.63 | 76.36 | 22.52 | 47.93 | 56.64 | 0.00 | 2.01 | |||
Days Payable | 511.89 | 389.55 | 391.01 | 320.68 | 729.22 | 3,974.44 | 13,253.28 | 1,611.83 | ||||
Cash Conversion Cycle | -415.97 | -252.14 | -307.12 | -206.97 | -705.13 | -3,926.52 | -13,196.64 | 421.15 | -1,580.31 | |||
Working Capital Days | -877.24 | -1,058.87 | -1,437.41 | -1,634.72 | -1,490.33 | -10,756.62 | -19,392.61 | -3,650.00 | 286.29 | |||
ROCE % | -13.63% | -17.80% | -22.31% | -34.09% | -59.62% | -12.82% | -21.98% | -7.41% | 36.90% | -4.27% | 9.93% | 11.53% |
Documents
Announcements
- Compliance Certificate Under Regulation 7(3) Of SEBI (LODR) Regulations, 2015 For The Financial Year Ended 31St March, 2024. 18 Apr
- Compliance Certificate Under Regulation 40(9) And 40(10) Of SEBI (LODR) Regulations, 2015 15 Apr
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 12 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
10 Apr - DP) Regulations, 2018, we enclose herewith a confirmation certificate received from MCS Share Transfer Agent Limited, RTA of the Company for the period ended 31.03.2024. …
- Closure of Trading Window 30 Mar
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
ASE is a pharmaceutical health care companies, which through its group companies, manufactures and markets pharmaceutical, molecular diagnostics, and electronics products in India and abroad